We used mutant yeast and human TBP molecules with an altered DNA-binding specificity to examine the role of TBP in transcriptional activation in vivo. We show that yeast TBP is functionally equivalent to human TBP for response to numerous transcriptional activators in human cells, including those that do not function in yeast. Despite the extensive conservation of TBP, its ability to respond to transcriptional activators in vivo is curiously resistant to clustered sets of alanine substitution mutations in different regions of the protein, including those that disrupt DNA binding and basal transcription in vitro. Combined sets of these mutations, however, can attenuate the in vivo activity of TBP and can differentially affect response to different activation domains. Although the activity of TBP mutants in vivo did not correlate with DNA binding or basal transcription in vitro, it did correlate with binding in vitro to the largest subunit of TFIID, hTAFnZSO. Together, these data suggest that TBP utilizes multiple interactions across its surface to respond to RNA polymerase II transcriptional activators in vivo; some of these interactions appear to involve recruitment of TBP into TFIID, whereas others are involved in response to specific types of transcriptional activators.
RNA polymerase II transcription in higher eukaryotes is regulated by a diverse range of sequence-specific tran scription factors, which act in combination to signal the transcriptional machinery to initiate transcription (for review, see McKnight and Yamamoto 1992) . Although much emphasis has been placed on how activators stim ulate the basal machinery in vitro (for review, see Tjian and Maniatis 1994) , little is known of the way in which the basal factors respond to activators in vivo.
Transcriptional activators appear to work in vitro by stimulating the ordered assembly of general transcrip tion factors (GTFs) at a promoter, forming a preinitiation complex that can initiate transcription (for review, see Zawel and Reinberg 1993) . For TATA box-containing, RNA polymerase Il-transcribed genes, formation of this complex begins with binding of the TATA box-binding protein (TBP) and its associated factors (TAFs) to the TATA box, followed by the sequential addition of other GTFs including RNA polymerase 11 (for review, see Buratowski 1994) . By targeting one or more of the general factors and facilitating their entry onto the promoter, activators can significantly enhance the rate of in vitro preinitiation complex assembly (Lieberman and Berk 1991, 1994; Choy and Green 1993) .
The process of activation in vivo, however, may be different. For example, the response of the fractionated GTFs to activators during preinitiation complex assem bly in vitro may not fully reflect the in vivo situation, because the GTFs may exist in large multicomponent complexes (Thompson et al. 1993; Kim et al. 1994; Koleske and Young 1994) ; the mechanisms that activate such complexes may differ from those that affect the isolated GTFs in vitro. In addition, although most in vitro studies examine single rounds of transcription ini tiation, the processes of activated reinitiation are likely to be more important for activator function in vivo, as activators can sustain high levels of transcription from the one or two functional gene copies within a cell.
Of the general transcription factors, TBP is studied most extensively (for review, see Hernandez 1993) . It is a highly conserved protein, containing a 180-amino-acid carboxy-terminal domain of known structure (Niklov et al. 1992 ; J.L. Y. Kim et al. 1993 ) that shares >80% sequence identity between yeast and hu mans. TBP plays an important role in transcriptional ac tivation in vitro, both as a direct target for activators (Ingles et al. 1991; Lieberman and Berk 1991; Truant et al. 1993; Emili et al. 1994) and by its association with other target proteins, including TFIIB and the TAFs (for review, see Goodrich and Tjian 1994) . The association of TBP with TAFs (forming the TFIID complex) is particularly important to the process of activation, as the TAFs are essential for activated tran scription but dispensable for basal transcription in vitro (Dynlacht et al. 1991; Tanese et al. 1991; Zhou et al. 1993) and bridge activators to other components of the transcriptional machinery (for review, see Tjian and Maniatis 1994; Chen et al. 1994) .
Previous studies of TBP in vivo have focused on the isolation of temperature-sensitive mutants in yeast. These studies have provided genetic evidence that TBP is involved in transcription by all three classes of RNA polymerase (Cormack and Struhl 1992; Schultz et al. 1992 ) and have identified a surface of TBP, spanning the two largest a-helices, that is required for RNA polymer ase III transcription (Cormack and Struhl 1993) . Such analyses are limited, however, to the isolation of mu tants that generate a conditional growth phenotype, and to date no TBP mutants specifically defective for acti vated RNA polymerase II transcription have been iden tified by this approach. In addition, as some activation domains, such as those from the human transcription factor Spl, do not display activity in yeast (Emili et al. 1994; Kunzler et al. 1994) , an analysis in human cells can better probe how a wide variety of nonconserved activa tors act on the relatively conserved basal transcriptional machinery.
In this paper we investigate the role played by TBP in activated RNA polymerase II transcription in human cells. We show that this activity of TBP in vivo involves numerous interactions across the surface of the mole cule and that different regions of TBP participate in re sponse to different transcriptional activators. Much of the behavior of TBP in vivo appears to reflect the nature of the association between TBP and the largest subunit of TFIID, hTAFn250. These data underscore the impor tance of TBP-TAF interactions for activated transcrip tion but also reveal that TBP functions in other ways to respond to transcriptional activators in vivo.
Results

Experimental design
The structure of the conserved carboxy-terminal domain of TBP is represented in Figure 1 . The underside of the saddle-like structure (shown in Fig. IB ) contains eight antiparallel p-sheets (Niklov et al. 1992 ) that form the DNA-binding surface of TBP (J.L. Y. Kim et al. 1993) . Accordingly, when TBP is bound to the DNA, much of the opposite surface of the molecule, in cluding the four a-helices and many of the loops con necting the p-strands, should be available for interaction with other proteins.
To monitor the activity of TBP in human cells, we used the altered-specificity TBP assay first described by Strubin and Struhl (1992) . This assay employs a TBP de rivative with a triple amino acid substitution on its DNA-binding surface (indicated in orange in Fig. 1 ). This TBP derivative (TBP^g) has a relaxed DNA-binding spec ificity and recognizes both a canonical TAT AAA box and an altered TGTAAA box (Strubin and Struhl 1992) . The combination of TEP^s and the TGTAAA box circum vents the activity of endogenous wild-type TBP in yeast (Strubin and Struhl 1992) , plant (Heard et al. 1993) , and mammalian (Keaveney et al. 1993 ) cells and thus allows the effects of in vitro manipulations in TBP to be exam ined in vivo.
We introduced various mutations into TBP^g and an alyzed the in vivo effects of these mutations on response to a battery of different transcriptional activation do mains, each fused to the heterologous yeast GAL4 DNAbinding domain (residues 1-94; Carey et al. 1989) . The structure of these GAL4-fusion activators is represented in Figure 2A . Spl*^ contains two copies of the glutaminerich Spl B domain (Courey and Tjian 1988) and was cho sen because it activates transcription in human but not yeast cells (Kunzler et al. 1994) . Oct-2^ and Oct-2^ are both derived from the human transcription factor Oct-2 but have distinctly different amino acid compositions: Oct-2^ consists of four copies of an 18-amino-acid glutamine-rich segment from the amino-terminal activa tion domain of Oct-2 , whereas Oct-2^ carries two copies of a 42-amino-acid proline-rich activation domain from the carboxyl terminus of Oct-2 . CTF^ and VP16 both carry singlecopy activation domains from CTF (Mermod et al. 1989) and the herpes simplex virus tians-sictivsitor VP16 (Triezenberg et al. 1988) , respectively. Figure 2A also lists the relative activity of the various GAL4-fusion activators on the wild-type counterpart of the TGTAAA-containing c-/os reporter used in these studies (see below). Because the VP16 activation domain was much more active than the other activation do mains examined, the amino-(VP16N) and carboxy-(VP16c) terminal halves of this domain (Regier et al. 1993) were also assayed individually. These truncated VPI6 activation domains displayed activities similar to those of the other activators (see Fig. 2A ). Figure 2B shows the structure of the wild-type and TGTAAA-containing c-/os reporters. The wild-type TAT AAA reporter construct contains the c-/os promoter to position -56 (Berkowitz et al. 1989) linked to four upstream synthetic GAL4 DNA-binding sites. The TGTAAA reporter is identical, except for the single A ^ G transition in the TATAAA box (TATAAA to TG TAAA). As shown below, this mutation in the c-/os pro moter disrupts activation in the presence of wild-type TBP but not TBPAS-The disruption of wild-type TBP activity by the TGTAAA mutation was promoter spe cific; a corresponding mutation in the p-globin promoter did not attenuate in vivo transcriptional activity (data not shown).
TBP and GAL4-fusion activator molecules were tran siently coexpressed with the c-/os reporter constructs in human HeLa cells. Correctly initiated transcripts from the c-fos reporters and from an a-globin internal control plasmid were quantitated by RNase protection analysis. The a-globin signals were used to normalize for differ ences in transfection efficiency and were not detectably affected by transient expression of exogenous TBP at the (Niklov et al. 1992) ; the yeast TBP structure is similar (Y. and is likely to be the conformation adopted by human TBP in this region. The a-carbon backbone is shown in white, and the position of the three altered-specificity (AS) substitutions (Strubin and Struhl 1992) are shown in orange. (Red) Position of the alanine substitution mutations HI and HI'; (green) position of the H2 and H2' mutations; (purple) position of the mutations on the two loops connecting strands S3/S4 and S3'/S4'. These mutations are described in detail in Table 1 . levels used in these experiments (data not shown). Ex pression of the mutant TBP^s molecules was monitored by quantitative Western blot analysis of protein extracts from transfected cells (data not shown), hi all experi ments the amount of TEP^s expression construct used was adjusted to give equivalent levels of expression for each TBP AS. Figure 3 shows the response of wild-type and mutant TBPAS molecules to each of the GAL4-fusion activators. Because the different activators possess very different relative activities (see Fig. 2A ), different length expo sures are shown for each activator. The wild-type TATAAA c-fos promoter responded well to the different activation domains examined (Fig 3, cf . lanes 1 and 2, panels A-G; see also Fig. 2A) . Introduction of the TG-TAAA mutation in the c-/os promoter significantly at tenuated the transcriptional response (cf. lanes 2 and 4), from between 12-fold for VP16 (E) to 17-fold for Oct-2Q (B). Transient coexpression of full-length human TBP AS (lane 6), but not an equivalent amount of wild-type hu man TBP (lane 5), restored transcriptional activation (cf. lanes 2 and 6, A-G). Activation by TEP^s (lane 6) was still dependent on expression of the GAL4 activator (data not shown). The difference in c-/os promoter activity ob served in the absence (lane 4) and the presence (lane 6) of TBPAS provides the assay for wild-type and mutant TBPAS function in response to each of the activators.
The activity of TBP^s was not dependent on the nonconserved amino-terminal region of human TBP (resi dues 2-159), as its deletion (AN; cf. lanes 6 and 7, A-G) did not diminish response to any of the GAL4-fusion activators examined-indeed, the Oct-2^ and VP16N ac tivators were three-to fivefold more active with the amino-terminally truncated TBP (cf. lanes 6 and 7, C and F). These data show that the nonconserved region of TBP is dispensable for RNA polymerase II transcriptional ac tivation in human cells as it is in vitro (Kelleher et al. 1992; Zhou et al. 1993) and in yeast cells (Cormack et al. 1991) and enabled us to confine our further mutational analysis to the conserved carboxy-terminal region of the protein.
Human and yeast TBP support equivalent levels of transcriptional activation in human cells
The carboxy-terminal 180 amino acids of human and yeast [Saccharomyces cerevisiae] TBP are 81% identical and are interchangeable for basal transcription and re sponse to acidic activators in vitro (Kelleher et al. 1992) and in vivo (Strubin and Struhl 1992; Keaveney et al. 1993) . Despite this high degree of sequence conservation, yeast TBP cannot replace human TBP for response to an "El A-like" activity in mouse embryonic carcinoma (EC) cells (Keaveney et al. 1993 ) and does not respond to Spl activation domains in yeast (Emili et al. 1994; Kiinzler et al. 1994) . To investigate functional differences between human and yeast TBP, we therefore assayed the ability of yeast TBP to respond to our panel of activation domains in human cells.
As shown in Figure 3 , yeast and human TBP^s re sponded similarly to all of the GAL4-fusion activators examined (cf. lanes 6 and 14, A-G). Thus, yeast TBP can respond to a wide array of mammalian activation do mains in human cells. In particular, there was no signif icant difference in human and yeast TBP AS response to Spl*-^ (A), demonstrating that although the activation do mains of Spl do not activate transcription in yeast, yeast TBP can support activation by Spl in human cells. This result suggests that the role TBP plays in activated tran scription has been conserved between yeast and humans but that the accessory factors required for Spl activation are not conserved between these species. [A] GAL4-fusion activators. Activa tion domains are classified as either glutamine-rich (Q-rich), proline-rich (P-rich), or acidic and were expressed as fusions w^ith the yeast GAL4 DNA-binding domain (GAL4 DBD; residues 1-94). Spl^ was con structed by duplicating the B domain of Spl (Courey and Tjian 1988) . The other activa tion domains have been described [4xQiiji8 ; 2xP*^ ; CTF (Mermod et al. 1989); VP16N (413-456), VP16c(452-490) , and VP16(413-490) (Triezenberg et al. 1988; Regier et al. 1993) ]. (A) GAL4 DNA-binding domain alone. Relative activity refers to the maxi mal level of activation of the wild-type (TATAAA) c-/os reporter by each of the GAL4-fusion activators, setting the level of activation by the weakest activator, Spl*^, to 1.0.
[B] The wild-type (TATAAA) and al tered (TGTAAA) c-/os reporter constructs. Both reporters contained the c-fos (-56) promoter (Berkowitz et al. 1989 ) down stream of four synthetic GAL4 DNA-bind ing sites .
TBP activity in vivo is not greatly affected by clustered point mutations
To examine the regions of TBP that are involved in re sponse to different activation domains in vivo, we con structed 10 amino acid substitution mutants as de scribed in Table 1 . Tw^o sets of mutant TBPs were gen erated. The first set, IIA and pol III, was based on temperature-sensitive mutations that had been de scribed for yeast TBP (Buratowski and Zhou 1992; Schultz et al. 1992) and were introduced at correspond ing positions in both yeast and human TBP^s-The IIA mutation is a double lysine to leucine substitution on the surface of helix 2 that disrupts interaction of yeast TBP with human TFIIA in vitro (Buratowski and Zhou 1992) ; it is not known whether this double leucine sub stitution in human TBP affects association with human TFIIA in vitro. The pol III mutation changes a conserved proline near the amino terminus of the TBP core to serine and disrupts transcription by RNA polymerase III but not RNA polymerase II (Schultz et al. 1992; S. Hahn, pers. comm.) . The second set of mutations consisted of a series of systematic alanine substitutions on the solvent-exposed surface of DNA-bound human TBP, targeting the four a-helices {HI, HI', H2, and H2'] and two prominent loops connecting strands S3 and S4 [S3/S4] and S3' and S4' {S3'/S4']. Figure 1 shows the position of these muta tions on the TBP structure. In an attempt to disrupt hu man TBP activity, for each mutation we made double and, in one case {H2], triple alanine substitutions and focused on residues whose charge is conserved in TBPs from many species. Mutations at corresponding posi tions were made in each symmetrical half of the mole cule except in helices H2 and HI', where the position of charged residues is not strictly conserved between each repeat. Curiously, two of these TBP^s mutants, HI and H2' as well as the yeast pol III mutant could not be expressed in HeLa cells (Table 1 ). The reason for this lack of expression is not known, but a similar phenomenon has been described for other TBP mutants in yeast (Reddy and Hahn 1991) and may reflect incorrect protein folding (Parsell and Sauer 1989) .
The ability of the mutant TBPs to support activation by the GAL4-fusion activators is shown in Figure 3 (lanes 8-13,15). The most notable feature of this analysis is that none of the mutations had a greater than threefold effect on the activity of TBP in vivo. In the context of yeast TBP^s/ the IIA mutation reduced response to all activators approximately twofold (cf. lanes 14 and 15, A-G). When the corresponding mutation was placed in the context of human TBP^s/ it modestly impaired acti- All other TBPs carried the altered-specificity sub stitutions and are described in Table 1 . Only the correctly initiated c-/os transcripts, normalized to the a-globin signal, are shown. Transient expres sion of TBPAS i^i the absence of a GAL4-fusion activator did not detectably increase transcription from the c-/os TGTAAA reporter or affect the a-globin signal (data not shown). As these GAL4-fusion proteins activate transcription to different overall levels ( Fig, 2A) , exposure time for each autoradiograph is different. vation only by the VP16-derived activators (cf. lanes 6 and 8, E-G) and not the other activation domains exam ined (A-D). Therefore, despite the defect in interaction with human TFIIA in vitro, the yeast IIA mutant-and its human counterpart-can still respond to RNA poly merase II transcriptional activators in vivo. Similarly, the pol III mutation (lane 9) had only a small effect on transcriptional activation, again predominantly by the VP16-derived activators. This result is consistent with the ability of the pol III mutant TBP to support tran scription by RNA polymerase 11 in yeast (S. Hahn, pers. comm.). Curiously, the transcriptional effects of the systematic set of multiple alanine substitution mutations were also small and mainly confined to activation by the VP16-derived activation domains (Fig. 3 , cf. lane 6 with lanes 10-13). The only reproducible effect was observed with the H2 mutant TBPAS, which was reduced two-to three fold in response to VP16. Comparison of full-length VP16 (lane 11, E) with its two less active subdomains (Fig. 3 , F,G; see Fig. 2A ) shows that the small selective effects of these mutations on VP16 activation do not simply result from its significantly greater transcrip tional activity, because VPISN, which displays an activ ity similar to that of CTF^, mirrored the response of full-length VP16 and not CTF^ to each of the TBP mu tations (cf. lanes 10-13, D-F).
The resistance of TBP activity in vivo to the effects of the multiple alanine substitutions was unexpected, given the high degree of sequence conservation in TBP across many species. It suggests that either these muta tions are not in regions of the protein that are involved in supporting activated transcription in vivo or that impor tant regions of TBP were being targeted, but the muta tions are not themselves sufficient to debilitate TBP ac tivity.
Mutations in TBP that do not affect activity in vivo have large effects in vitro
In a parallel series of experiments, we examined the po tential of the systematic set of multiple alanine substi tution mutants to bind DNA and to support basal tran scription in vitro. We analyzed the HI', H2, S3/S4, and S3'/S4' mutants because they are expressed in HeLa cells, allowing a comparison of in vitro and in vivo ac tivities.
Full-length HI', H2', S3/S4, and S3'/S4' TBP^s mole cules were expressed in Escherichia coli and purified as fusions with glutathione S-transferase (GST) sequences. The DNA-binding capability of these GST-TBP^s mu tants was then examined by DNase I footprinting anal ysis, as shown in Figure 4 . Titration of wild-type TBP^s on the TGTAAA c-fos promoter produced two clear re gions of protection (cf. lane 2 with lanes 3-5): a region encompassing 6 bases 5' and 4 bases 3' of the TGTAAA sequence and a region containing an A/T-rich vector sequence upstream of the GAL4 DNA-binding sites. In contrast, titration of identical amounts of the mutant TBPs produced patterns of DNase I protection that dif fered from wild-type TEP^g. Binding of the HI' and S3/S4 mutants, although detectable, was reduced ~ 10-fold (cf. lanes 3-5 with lanes 6-8 and 12-13), whereas the S3'/S4' mutant TEP^s did not bind DNA to any signif icant degree (cf. lanes 3-5 with lanes 15-17). By compar ison, the H2 mutant bound DNA at levels similar to wild-type TBP^s (cf. lanes 3-5 with lanes 9-11); the binding of this mutant TBP^s, however, produced a imique DNase I hypersensitive site 3 bases 5' to the pro tected region (see arrow), possibly reflecting a different conformation of the TBP-DNA complex. As the HI', H2, S3/S4, and S3'/S4' TBP^s molecules can support activated transcription in vivo, these in vitro-binding data indicate that the ability of TBP to bind DNA in vitro does not necessarily correlate with its ability to function for activated transcription in vivo. Similar discrepancies between the DNA-binding potential of TBP and its abil ity to support transcription in vitro and in yeast cells have been reported Struhl 1992,-Lee et al. 1992; Schultz et al. 1992; Yamamoto et al. 1992 ). Figure 5 shows the effects of the four sets of systematic alanine substitutions on the capacity of TBP^s to sup port basal transcription from the TGTAAA c-/os reporter in vitro. The results of RNase protection analysis per formed on RNA transcribed in crude HeLa cell nuclear extract reveal that in the absence of added wild-type GST-TBP^s/ no basal transcription was observed from this promoter (lane 1). Addition of wild-type GST-TEP^s resulted in a high level of correctly initiated transcripts (lane 2), whereas the two mutant TBP^^g molecules HI' and S3/S4, which bound DNA poorly, supported nearly wild-type levels of basal transcription (cf. lane 2 with lanes 3 and 5). In contrast, mutants H2 (lane 4) and S3'IS4' (lane 6) showed no detectable basal activity in this assay, even though the H2 mutant binds well to DNA (Fig. 4) . Taken together with the in vivo fimctional data (Fig. 3) , this result demonstrates that the ability of Cold
TBP to support basal transcription in vitro is not a pre requisite for its ability to support activated transcription in vivo. Moreover, this result, together with the DNAbinding studies described above, suggests that interac tion of TBP with cellular components in vivo can coun teract the effects of mutations in TBP that disrupt DNA binding {HI', S3/S4, and S3'/S4') or basal transcription (H2 and 537S4') in vitro.
Combined sets of mutations in different regions of TBP disrupt transcriptional activation in vivo
As the activity of TBP in vivo was relatively unaffected by mutations in single regions of the protein, we rea soned that the functioning of TBP may depend on mul tiple, redundant interactions at different points across its surface. One prediction of this hypothesis is that com bined mutations in different regions of TBP may have a significant effect on its activity in vivo. To explore this possibility, we made all combinations of the HI', H2, S3/S4, and S3'/S4' mutations and assayed the ability of the combined mutant TBP^s molecules to respond to the different activation domains in vivo. Figure 6 shows the response of Oct-l'^, CTF^, fulllength VP16, and VP16N to each of the combined sets of mutations in TBP^s-Also examined were the Oct-2^ and Spl^ activators, which yielded results similar to those of Oct-2*-* (data not shown). The combination of all four HI', H2, S3/S4, and S3'/S4' mutations in TEP^s (lane 13, A-D) disrupted the ability of TBP to respond to any of the activation domains examined. Analysis of the double (lanes 3-8) and triple (lanes 9-12) combined sets of mu tants, however, revealed that the activity of TBP in vivo is sensitive only to specific combinations of these mu tations.
Certain combined sets of mutations produced consis tent effects on activated transcription, regardless of the In contrast to these universal effects on TBP^s re sponse to activators, certain combined mutations pre dominantly affected activation by the VP16 activation domain, hi particular, the HI'+ S3/S4 + S3'/S4' triple combination supported wild-type levels of activation by CTF^ but was <10% active for response to VP16 (Fig. 6 , lane 11, cf. B and C). Curiously, unlike the response to single sets of mutations (see Fig. 3 ), the response of each 2762 
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Cold Spring Harbor Laboratory Press on November 3, 2017 -Published by genesdev.cshlp.org Downloaded from TBP tesponse to activators in vivo of the combined sets of mutations to VP16N more closely mirrored the response to Oct-2^ and CTF^ than to full-length VP16. This comparison raises the possibil ity that the VP16-specific defect of the Hl' + S3/S4 + S3'/S4' mutant TBP^s is a result of the high activity of the full-length VP16 activation domain. The activation domain-specific defect of this mutant TBP makes two important points: (1) It shows that, although the HI' + S3/S4 + S3'/S4' mutant TBP is only weakly active for VP16, this loss of activity is not the result of a general ized disruption of the integrity or accessibility of the TBP, because it functions at wild-type levels for CTF^, and (2) it demonstrates that activators can differ in how they directly or indirectly utilize different residues in TBP to activate transcription.
Interaction of TBP with hTAPii250 is resistant to mutations in single regions of TBP but is disrupted by specific combinations of mutations
The ability of different mutant TBPs to support activated transcription in vivo did not correlate with their ability to interact with DNA or to support basal transcription in vitro. To probe the mechanisms that dictate TBP activity in vivo, we investigated the effect of our alanine substi tution mutations on the interaction of TBP with two other components of the transcriptional apparatus. Be cause TBP only supports activated transcription in vitro when assembled into a partial or complete TFIID com plex (Dynlacht et al. 1991; Tanese et al. 1991; Zhou et al. 1993; Chen et al. 1994 ), we examined mutant TBP asso ciation with hTAFn250 in vitro. Human TAFn250 binds directly to TBP and appears to form a scaffold for the assembly of TFIID (Goodrich et al. 1993; Ruppert et al. 1993; Weinzierl et al. 1993; Verrijzer et al. 1994; ; thus, the ability of TBP to interact with hTAFii250 is probably a good measure of its ability to be recruited into TFIID. Additionally, hTAFn250 has been shown to be crucial for transcriptional activation in vivo (Wang and Tjian 1994) . However, although the carboxyterminal core of TBP is sufficient for the assembly of an active TFIID complex (Zhou et al. 1993) , little is known about the residues in the core of TBP that are required for association of TBP with hTAFii250. In addition, we also examined interaction of these mutant TBP molecules with TFIIB in vitro, as TFIIB is known to interact with both TBP and activator proteins in vitro Ha et al. 1993 ) and has been implicated as an important functional target for transcriptional activators .
In vitro-translated radiolabeled wild-type and mutant TBPAS molecules were mixed with hemagglutinin influ enza virus (HA) epitope-tagged hTAFn250 or GST-TFIIB and either coimmunoprecipitated with antibodies against the HA-epitope tag (hTAFu250) or cobound to glutathione beads (TFIIB). After extensive washing, the labeled TBP that remained bound to the precipitated hTAFn250 or TFIIB was analyzed by SDS-PAGE followed by autoradiography. The presence of the altered-specificity substitutions did not affect the ability of wild-type TBP to interact with either hTAFn250 or human TFIIB in vitro (data not shown). Figure 7 shows the results of these experiments. Figure 7A shows 10% of the input TBP for each assay. As a negative control for the TBPhTAFii250 interaction, we also examined the interaction of labeled mutant TBPAS molecules with beads carrying just the anti-HA antibody: Binding of labeled TBP^^s to these control beads (Fig. 7D ) was ~1% that of binding to beads containing hTAFii250. In a siinilar control exper iment for the interaction of TBP with GST-TFIIB, we found that ~ 10-fold more TBP^s bound to GST-TFIIB beads than to GST-alone beads (data not shown).
None of the mutations, including the quadruple com bination mutation HI'+ H2 + S3/S4 + S3'/S4' (lane 16), had a large effect on the interaction of TBP with human TFIIB (cf. Fig. 7, A and C) . This result suggests that these mutations do not target the residues of TBP that interact with TFIIB under these conditions and is consistent with the finding that large regions of TBP can be deleted with out disrupting the TBP-TFIIB interaction in this type of assay (Ha et al. 1993) .
In contrast, the ability of these TBP molecules to in teract with hTAFn250 was strongly affected by some of the mutations (cf. Fig. 7 , A and B). As with in vivo tran scriptional activity, the interaction of hTAFii250 with TBP was largely resistant to the effects of mutations in single regions of TBP. The only single regional mutation that had a detectable effect was the H2 mutation, which reduced twofold the ability of TBP^s to interact with hTAFn250 (Fig. 7B, cf. lanes 1 and 3) . When different mutations on the surface of TBP were combined, inter action between TBP and hTAFn250 could be strongly affected. In particular, any combinations of the H2 and S3'/S4' mutations (lanes 10,13,15,16) reduced the ability of TBP to interact with hTAFii250 to 10% or less of wild-type levels. These data suggest that TBP interacts with hTAFii250 by making multiple contacts across its surface and that any one point of interaction between TBP and hTAFii250 can be disrupted without disrupting the overall integrity of the TBP-hTAFn250 association.
In Figure 7E , the interaction of the various mutant TBP molecules with hTAFn250 is summarized and com pared with the results of CTF^ and VP16 activation in vivo. Generally, the ability of wild-type and mutant TBP molecules to respond to transcriptional activators in vivo closely paralleled their ability to interact with hTAFji250 in vitro. In particular, all mutations in TBP that reduced interaction with hTAFii250 in vitro by 10-fold (columns 10,13,15,16, E; those that carry the H2 + S3'/S4' combination) were defective for transcrip tional activation in vivo. Similarly, the mutant TBP mol ecules carrying double or triple combinations of the HI ', S3/S4, and S3'/S4' mutations (columns 7,8,11,14) retain considerable in vivo activity for response to CTF^ and associate better with hTAFii250 than the less active mu tants. The VP16-derived activator, however, did not ac tivate transcription at full potential even when TBP could associate effectively with hTAFii250, albeit at a lower level, as in the case of the HI'+ S3/S4 + S3'/S4' triple mutant (column 14) . This result suggests that to reach its full activation potential, VP16 requires more than simply the ability of TBP to associate with hTAFn250. Given the marked differences in the assays used to measure TBP activity in vivo and its interaction with hTAFn250 in vitro, the qualitative similarities in the activation and hTAFii250-association profiles are strik ing. These data suggest that the resilient nature of the interaction of TBP with hTAFnlSO is the reason why TBP activity in vivo is resistant to single sets of amino acid substitutions. They also suggest that interaction of TBP with hTAFn250 plays a central role in the response of TBP to a diverse range of transcriptional activation domains.
Discussion
TBP performs a range of diverse activities within the cell. It is involved in transcription by all three nuclear RNA polymerases, from promoters with or without a TATA box. TBP achieves much of this diversity by in teracting with different sets of TAFs, depending on the polymerase and promoter context (see Hernandez 1993; Goodrich and Tjian 1994) . These many different physical associations probably place large constraints on the structure of TBP, which may explain why the carboxyterminal core of the protein has been so highly conserved throughout evolution.
We have studied the surfaces of TBP that are required in vivo for just one of its many functions: activated RNA polymerase II transcription from a TATA box-containing promoter. The highly conserved TBP core is sufficient to respond to a battery of different activation domains in human cells, but, to our surprise, the high degree of se quence conservation in this region of the molecule is not required (Fig. 3) . Indeed, TBP can withstand multiple amino acid substitutions within individual regions of the conserved domain without losing the ability to re spond to the activators tested in our transient expression assay. This result suggests that it is likely to be other aspects of TBP function that constrain its evolutionary sequence divergence.
One possible constraint is the role played by TBP in RNA polymerase III transcription. When single amino acid substitutions within the top surface of TBP (as rep resented in Fig. lA ) that affect yeast cell viability have been identified, they predominantly affect RNA poly merase III transcription (Cormack and Struhl 1993; Cormack et al. 1994 ). This result could simply mean that the top surface of TBP has little involvement in transcrip tion by RNA polymerase 11. Alternatively, the activity of yeast TBP in RNA polymerase II transcription may also be resistant to single amino acid substitutions; perhaps combinations of amino acid substitutions in yeast TBP, as in human TBP, would affect its activity in RNA poly merase II transcription.
Transcription by RNA polymerase II differs signifi cantly from that by the other RNA polymerases, because RNA polymerase II must respond to many different se quence-specific transcription factors. The coactivator hypothesis (Pugh and Tjian 1992) posits that complexed with TBP are proteins-coactivators-that serve as in termediaries between activators and RNA polymerase II. Indeed, TAFs display coactivator activity (Dynlacht et al. 1991; Tanese et al. 1991; Chen et al. 1994) . Coactivators thus permit the activity of diverse sequence-specific ac tivators to be directed toward activation of a single RNA polymerase. By virtue of its ability to bind to both the TATA box and TAFs, TBP targets coactivators to TATA box-containing promoters. The correlation described here between TBP-TAF interaction in vitro and the re sponse of TBP to many different activation domains in vivo (Fig. 7E) is consistent with this hypothesis.
The ability of yeast TBP to respond to a variety of transcriptional activation domains in human cells (Fig.   3) suggests that, during evolution, the interface between TBP and other components of the transcriptional ma chinery has been conserved. This conserved interface could well be that between TBP and the TAFs. Like hu man cells, yeast contain TAFs (Poon and Weil 1993) , including a direct structural homolog of the human TBPbinding TAFH250 (A. Weil, pers. comm.) . Furthermore, yeast TBP can bind hTAFnlSO in vitro (S. Ruppert and R. Tjian, unpubl.) . Thus, this TBP-TAF interaction, which is involved in recruiting TBP into the TFIID complex, has been evolutionarily conserved, perhaps reflecting its universal importance to activated RNA polymerase II transcription in vivo.
Although the activation domains of Spl (Kiinzler et al. 1994) and Oct-l^ (C. Hinkley and W. Herr, unpubl.) do not function in yeast, they can activate transcription with yeast TBP in human cells (Fig. 3) . This finding sug gests that one or more elements other than the interface between TBP and the transcriptional machinery have diverged between yeast and humans. One possibility is that the full complement of TFIID TAFs has not been universally conserved. For example, Drosophila TAFijllO responds to a glutamine-rich activation do main from Spl Chen et al. 1994 ): Perhaps in yeast either this TAF is absent or a homolog has lost the ability to respond to the Spl activation do main. Such changes in TAFs could result in changes in transcriptional response to entire classes of activation domains during speciation or even during cell differen tiation if TAF expression is developmentally controlled.
To contrast the activity of TBP point mutants in vivo with their in vitro activities, we assayed the effects of clustered alanine substitution mutations in four in vitro assays: (1) basal transcription, (2) binding to DNA, (3) association with TFIIB, and (4) association with hTAFn250. Only the association with hTAFii250 corre lated with in vivo activity (Fig. 7) . TFIIB association was unaffected by any of the mutations (Fig. 7) , whereas both DNA binding and basal transcription in vitro (Figs. 4 and 5) were disrupted by individual sets of point mutations that had little if any effect in vivo. It is known that defects in DNA binding by yeast TBP can be overcome in vivo and during in vitro basal transcription (Cormack and Struhl 1992; Lee et al. 1992; Schultz et al. 1992; Yamamoto et al. 1992) .
We were surprised, however, that human TBP mutants that supported activated transcription in vivo could be defective for basal transcription in vitro. We imagined that the ability to support basal transcription would be a likely prerequisite for TBP to respond to activators. As suggested above, perhaps the interactions of TBP in vivo with cellular components can counteract the effects of these TBP mutations. A good candidate for such an in teraction is that between TBP and TAFs in TFIID and, in particular, between TBP and hTAFii250, which recruits TBP into TFIID (Ruppert et al. 1993; Weinzierl et al. 1993; Chen et al. 1994) .
The association of hTAFn250 with TBP in vitro ap pears to involve interactions with multiple surfaces of TBP and is resistant to changes in isolated regions of TBP (Fig. 7) . These effects correlate with the in vivo activity of TBP and suggest an extensive and stable interaction between TBP and TAFH250. Although we do not dis count the possibility that the effects of these mutations on hTAFii250 interaction could be indirect, such an ex tensive interaction is consistent with the stable associ ation of TBP with TAFs in the TFIID complex (Dynlacht et al. 1991; Tanese et al. 1991; Zhou et al. 1993) . It is also consistent with the observation that multiple regions of hTAFnlSO can independently interact with TBP in vitro (S. Ruppert and R. Tjian, xmpubl.) . But why does TBP rely on an extensive interaction with hTAFn250 across its surface in this way?
We propose that by utilizing multiple points of contact across its surface, TBP is able to interact with hTAFn250 and, in turn, a network of other TAFs in a way that is both strong and flexible. This may have several conse quences for the functioning of TBP in vivo. First, the resilience of the interaction of TBP with hTAFii250 raises the possibility that once TBP enters TFIID, it may not be available for interaction with the other TBP-containing complexes (such as SLl and TFIIIB; for review, see Goodrich and Tjian 1994) . As TBP is apparently lim iting for RNA polymerase II and III transcription (Cormack and Struhl 1993) , the distribution of TBP into the various TAF-containing complexes may have important consequences for coordinating transcription within the cell. Second, as there are multiple points of contact be tween TBP and hTAFQ250, it is possible that one or more of these individual interactions could be disrupted without destroying the overall integrity of the TBPhTAFn250 association. In this way, the precise nature of the TBP-hTAFii250 association could change, perhaps allowing TBP to also make direct contact with activators or with other GTFs.
In addition to the importance of the TBP-TAFn250 interaction for activated transcription we observe with all activators tested, there are elements of TBP function that selectively affect the activity of one but not other activation domains. This property is exemplified by the sensitivity of the VP16 activation domain to mutations that do not affect the activity of other activation do mains, in particular, the multiple regional point mutant Hl' + S3/S4 + S3'/S4', which severely disrupts activa tion by VP16 but not CTF^ (Fig. 6) . The behavior of this mutant TBP demonstrates that TBP itself, a single com ponent of the basal transcriptional machinery, can be used in different ways to achieve transcriptional activa tion.
The differential effects of the HI'+ S3/S4 + S3'/S4' mutant may reflect the unusual potency of VP16. Al though this combined mutation in TBP reduced VP16 activation by > 10-fold, the absolute level of activation achieved by VP16 in this instance is very similar to that seen with CTF^ ( Fig. 2A) . One possible mechanism for such an unusual potency is that VP16 has a greater range of targets in the transcriptional apparatus. This mecha nism is implied by the biochemical characterization of multiple potential targets for VP16, which thus far in clude TFIIB , TBP (Ingles et al. 1991) , and TAFn40 (Goodrich et al. 1993) . It is also consistent with the observation that VP16N was affected less severely by the H1' + S3'S4 + S3'/S4' mutation than the more active full-length acti vation domain (see Fig. 6 ). VP16 may thus achieve greater levels of activation by stimulating additional or different targets than CTF^: The HI'+ S3/S4 + S3'/S4' mutation may disrupt the interaction of TBP with these VP16-specific targets, either directly or by inducing changes in the hTAFii250-TBP complex that in some way weaken recognition by critical VPI6 coactivators, such as a human homolog of the Diosophila TAFu40 (Goodrich et al. 1993 ).
In conclusion, our in vivo and in vitro studies of TBP function suggest that TBP responds to activators by more than one pathway: one broadly used pathway involving association with TFIID through an extensive interaction with TAFn250 and a second pathway that may only be used by a selected set of activation domains, including the very potent VP16 activation domain.
Materials and methods
Constiuction of mutant TBP molecules and GAL4-activatois
TBP-encoding sequences were subcloned into the mammalian expression vector pCGN (Tanaka and Herr 1990) , which adds a 15-amino-acid HA epitope tag to the amino terminus of the expressed protein. To minimize translation initiation after the epitope tag, the full-length wild-type and altered-specificity hu man TBP pCGN clones [gifts from M. Tanaka and R. Mital, respectively (Cold Spring Harbor Laboratory)] were modified by site-directed in vitro mutagenesis (Kunkel et al. 1987) to remove sequences encoding the initiator methionine of human TBP. Yeast TBP sequences (encoding amino acids 2-240 of S. ceievisiae TBP) were amplified from genomic DNA (gift of K. Gavin, Cold Spring Harbor Laboratory) by the polymerase chain reac tion (PCR) with 5' Mi el-and 3' BamHI-adapter primers. After restriction enzyme digestion, the resulting fragment was subcloned into the unique Xbal and BamHl sites of pCGN and site-directed mutagenesis was used to introduce (1) the triple amino acid altered-specificity substitution (Strubin and Struhl 1992) and (2) two silent mutations at codons 61 and 62, which removed a cryptic splice-site donor that prevented expression of full-length yeast TBP in HeLa cells (W.P. Tansey and W. Herr, unpubl.). Single regional point mutations in human and yeast TBP {HI, HI', H2, H2', S3/S4, S3'/S4', IIA, and poi III] were generated by site-directed mutagenesis with single synthetic oligonucleotides carrying the desired mutations; multiple re gional point mutants were generated with a pool of the HI', H2, S3/S4, and S3'/S4' mutagenic oligonucleotides.
To prepare the pT^-TBP^s constructs for in vitro translation, inserts of the pCGNTBP^s constructs were amplified by PCR with 5' Ndel-and 3' BamHl-adapter primers. The products were digested with Ndel and BamHl and subcloned into pTpSTOP (gift of H. Jantzeu; Jantzen et al. 1992) to yield the corresponding pT^TBP^s constructs used for in vitro transcription/transla tion. The sequence integrity of all constructs was confirmed by dideoxy sequence analysis of the entire conserved region of TBP.
GAL4-fusion activators were constructed by subcloning var ious activator-derived sequences into the vector pCG-GAL(1-94) ; modified by C. Hinkley-to be de scribed elsewhere). The GAL4-CTF^ fusion was produced by PCR amplification of CTF sequences (encoding amino acids 399-499 of CTF; Mermod et al. 1989 ) from pSG + CTF (gift of N. Martinez et al. 1991) with 5' Xbal and 3' BamHl adapter primers and ligating the cleaved fragment into the unique Xbal and BamHI sites of pCG-GAL(l-94). Spl se quences (encoding amino acids 263-391 of Spl; Courey and Tjian 1988) were PCR-amplified from pSG + SplN [gift of G. Gill (University of California, Berkeley); Li et al. 1991] with 5' Bbsl-and 3' BamHI-adapter primers, cleaved, and ligated in tandem into the unique Bbsl and BamHl sites of pCG-GAL(l-94). This manipulation produced an in-frame fusion of the GAL4 DNA-binding domain with two copies of the Spl B do main, adding the sequence EDEPQSS between the two Spl re peats. The VP16N (413-456) and VP16c (452-490) GAL4-fusion constructs were produced by loop-out site-directed mutagenesis of the parental pCG-GAL( l-94)VP16(413-490) construct [gift of G. Das (Cold Spring Harbor Laboratory)].
Alteied-specificity TBP assay
HeLa cells were transiently transfected by the calcium phos phate coprecipitation method as described (Tanaka et al. 1992) . Each transfection included (1) 200 ng of c-/os reporter, either wild-type (gift of M. or carrying the TAT AAA to TGTAAA mutation (introduced by site-directed mutagenesis); (2) between 160 ng and 1.76 |xg of pCGNTBP expression plasmid (adjusted to give equivalent lev els of expression for each HA-tagged TBP); (3) between 350 and 720 ng of pCG-GAL4-activator expression plasmid (the amount for each determined empirically to give maximal activation of the wild-type c-/os reporter); (4) 80 ng of a-globin internal ref erence plasmid pa4x(A + C) (Tanaka et al. 1988) ; and (5) pUC119, taking the total amount of transfected DNA to 20 |xg. At 36 hr post-transfection, cells were harvested and cytoplasmic RNA prepared as described (Tanaka et al. 1992) . RNase protec tion analysis (Tanaka et al. 1992 ) was used to quantitate cor rectly initiated transcripts from the c-/os reporter and from the a4x( A + C) internal control plasmid. TBP expression levels were determined by transfecting threefold titrations of each expres sion construct, followed by Western blot analysis of protein extracts from transfected cells with an antibody probe (12CA5) against the HA epitope tag.
Pioduction of recombinant proteins
Altered-specificity TBP sequences were subcloned into the unique Xbal and BamHl sites of pETllcGST and expressed in E. coli as GST fusion proteins by use of the T7 expression system developed by Studier et al. (1990) . E. coli BL21(DE3) cultures of 500 ml carrying the appropriate pETllcGST-TBP^s construct were grown at 30°C to an OD595 of 0.6. At this point, IPTG was added (0.5 mM final concentra tion) and the cultures induced were for 4 hr at 30°C; growth and induction at this temperature resulted in the highest yield of soluble induced protein. After induction, cells were harvested by centrifugation, resuspended in 30 ml of lysis buffer [25 mM HEPES-KOH (pH 7.9 at 4°C), 20% glycerol, 12.5 mM MgCli, 2 mM EDTA, 2 mM DTT, 0.2 mM PMSF, 5 M-g/ml of aprotinin, 5 fx,g/ml of leupeptin, and 5 |xg/ml of pepstatin], and lysed by treatment with lysozyme (final concentration of 100 |xg/ml) and the addition of NP-40 to 0.1% (final concentration). The lysate was then sonicated to shear bacterial DNA, and insoluble pro teins were removed by centrifugation. GST-fusion proteins were purified from the soluble fraction by binding to 200 |xl of glutathione-agarose (Sigma) for 1 hr at 4°C, washing extensively with HEMGN buffer (Lieberman and Berk 1991) containing 0.15 M KCl, and eluting with two lots of 100 |xl of 5 mM reduced glutathione (in HEMGN with 0.15 M KCl). Samples of the eluates were analyzed by SDS-PAGE combined with Coomassie staining and Western blot analysis. Typically, a 500-ml culture yielded between 5 and 20 |xg of full-length GST-TBPAS, in a form that was essentially free of non-TBP-related proteins; these preparations did, however, contain a significant propor tion of inactive carboxy-terminal TBP breakdown products.
DNA-binding and basal transcription analyses
DNase 1 footprinting analysis was performed with purified re combinant GST-TBPAS fusion proteins. The c-/os TGTAAA probe was prepared by PCR from the c-/os (-56) [4xGAL] TGTAAA reporter with an vmlabeled reverse sequencing primer and an end-labeled primer that hybridized to c-/os promoter sequences sparming -I-6 to -I-23. Each binding reaction included 10,000 cpm of probe, 15-150 ng of full-length GST-TBP^s, 50 ng of poly[d(G-C)], 2% polyvinyl alcohol, 2 |xg of BSA, 12.5 mM HEPES-KOH (pH 7.9], 75 mMKCl, 0.1 mM EDTA, 10% glycerol, 5 mM MgClj, 1 mM DTT, 0.1 mM PMSF, and 0.05% NP-40, in a total volume of 25 |xl and was allowed to proceed for 40 min at 30°C. DNase I digestion was then carried out as described (Schmidt et al. 1989) , and reaction products were analyzed by denaturing poly aery lamide gel electrophoresis. G-l-A chemical sequencing reactions of the c-/os TGTAAA probe were run alongside the footprinting reactions.
In vitro transcription from the c-/os {-56)TGTAAA template was performed in crude HeLa cell nuclear extract (Dignam et al. 1983) supplemented with purified recombinant GST-TBPASReactions contained 4 | JL1 of nuclear extract (32 [jig of total pro tein), 160 ng of c-/os (-56) [4xGAL]TGTAAA reporter plasmid, 15 ng of the appropriate full-length GST-TEP^s fusion protein, 20 mM HEPES-KOH (pH 7.9), 62.5 mM KCl, 5 mM ammonium sulfate, 3% polyethylene glycol 8000, 8 mM MgClj, 10% glyc erol, 1 mM DTT, and 0.7 mM each of ATP, CTP, UTP, and GTP. After a 60-min incubation at 30°C, the reaction mixture was treated with proteinase K and SDS and extracted with phenol/ chloroform, and nucleic acids were precipitated with ethanol. RNA transcribed in vitro was then analyzed by RNase protec tion analysis ).
Coimmunoprecipitations and GST puUdowns
HA epitope-tagged hTAFii250 was expressed in baculovirus-infected SF9 cells and whole-cell extracts were prepared as de scribed (Ruppert et al. 1993) . After diluting the extract to HEMGN containing 0.3 M KCl (0.3 HEMGN) and clearing it by centrifugation, the supernatant was incubated for 4 hr on ice with anti-HA (12CA5) antibodies (BAbCO). The extract was cleared again by centrifugation, and the 12CA5 antibody and immunopurified hTAFii250 was precipitated from the superna tant by binding to protein A-Sepharose CL-4B beads (Pharma cia). The beads were washed extensively with 0.1 HEMGN and analyzed by SDS-PAGE and Coomassie staining. ^^S-Labeled TBPAS proteins were generated from the pTp-TBP^s constructs by in vitro transcription/translation using the TNT coupled re ticulocyte lysate system (Promega). The in vitro-translated pro teins were diluted with four volumes of 0.1 HEMGN and cleared by centrifugation. Fifty microliters of the supernatant was incubated with 25 [xl of packed protein A beads containing either 12CA5 and -200-300 ng of full-length hTAFii250 or 12CA5 alone. After nutating 3-4 hr at 4°C, bound TBP^s pro teins were recovered by low speed centrifugation and the beads were washed extensively with 0.1 HEMGN. The bovmd pro teins, 10% of the input TEP^s, and an aliquot of the final wash were analyzed by SDS-PAGE, followed by silver-staining and autoradiography. Bound TBPAS proteins were quantitated by Phosphorlmaging and corrected for background binding to aHA |12CA5) beads and for minor variations in protein input.
GST-TFIIB and control GST proteins were expressed from the T7 expression vectors (gift of D. Reinberg; Ha et al. 1993 ) in E. coli DH5a, purified by binding to glutathione-Sepharose 4B beads (Pharmacia), and analyzed by SDS-PAGE and Coomassie staining. Beads containing 200-300 ng of GST-TFIIB fusion pro tein or 500 ng of GST alone were incubated with ^^S-labeled TBPAS and analyzed as described above. Approximately 10-fold more TfiP^s proteins were bound to the GST-hTFIIB beads than to the control GST beads.
